Has anyone transitioned from carboplatin/paclitaxel to Kisqali and anastrozole, and then to trametinib for stage 4 low-grade serous ovarian cancer?
Low-grade serous ovarian cancer (LGSOC) often responds differently to treatment than high-grade types. While carboplatin and paclitaxel are standard first-line chemotherapy drugs Show Full Answer
Has anyone transitioned from carboplatin/paclitaxel to Kisqali and anastrozole, and then to trametinib for stage 4 low-grade serous ovarian cancer?
Low-grade serous ovarian cancer (LGSOC) often responds differently to treatment than high-grade types. While carboplatin and paclitaxel are standard first-line chemotherapy drugs for ovarian cancer, LGSOC can be less responsive to traditional chemotherapy.
For LGSOC specifically, hormone therapy with drugs like anastrozole (an aromatase inhibitor) is commonly used because these cancer cells often have hormone receptors. Targeted therapies are also being studied in clinical trials for LGSOC.
The treatment sequence you're asking about—moving from chemotherapy to hormone therapy combined with targeted drugs, then to trametinib (which targets specific genetic mutations)—reflects the evolving approach to treating LGSOC. This progression suggests your care team is tailoring treatment based on how your cancer responds and its specific characteristics.
Since LGSOC is less common and treatment approaches can vary significantly, connecting with others who've had similar treatment paths on MyOvarianCancerTeam could provide valuable insights about their experiences with these specific medications.
January 6
Join
Your Privacy Choices
